TrialCancer2021

Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.

Bradley Alexander McGregor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.